Partnership for Safe Medicines India Initiative Hosts National Multi-Stakeholder Forums to Help Protect Patients

08.28.13 | By

Across the globe, millions of patients are put at risk by counterfeit, substandard or otherwise unsafe medicines. As Executive Director of the Partnership for Safe Medicines in the United States, I traveled to India this week to participate in two national workshops hosted by the PSM India Initiative, an organization working to raise awareness and empower consumers across the country.

Clinical Trials in South Carolina

08.28.13 | By

At a time when there is growing concern about diversity in clinical trials, we learned yesterday that 26 percent of people who participate in treatment trials at the Medical University of South Carolina's Hollings Cancer Center (HCC) are African American.

Dr. Marvella E. Ford, HCC's associate director, cancer disparities, attributes that success to the center's comprehensive clinical trials education program at 17 facilities in 11 South Carolina counties.

PhRMA Foundation

08.27.13 | By

The PhRMA Foundation is seeking applications for its Young Investigator Center for Adherence Improvement Award. The award will provide stipend support for individuals who are doing research that will advance and improve medication adherence.

PhRMA Conversations - Clinical Trials Data Sharing and Patient Privacy

08.27.13 | By

Last month, PhRMA and the European Federation of Pharmaceutical Industries and Associations (EFPIA) endorsed joint Principles for Responsible Clinical Trial Data Sharing: Our Commitment to Patients and Researchers.

Rep. Clyburn among speakers at “Research in Your Backyard” press conference

The Medical University of South Carolina (MUSC) this morning hosted “Research in Your Backyard,” a press conference announcing the key findings of a new report from the Pharmaceutical Research and Manufacturers of America (PhRMA) that focuses on clinical trials being conducted by biopharmaceutical research companies and local research collaborators throughout South Carolina. Rep. James Clyburn was a featured speaker at the conference, which took place inside the Drug Discovery Building of the James E. Clyburn Research Center.

Clinical Trials are an Essential Option for Patients

08.26.13 | By

I recently learned of the International Cancer Advocacy Network which provides personalized assistance to patients facing stage IV cancer.  I invited Marcia Horn, President and CEO of ICAN, to elaborate on the mission and programs the organization offers.

Heightened Sense of Urgency to Come to an Agreement

08.26.13 | By

With the Asia-Pacific Economic Cooperation (APEC) leaders meeting scheduled for October and participating countries emphasizing their desire to complete Trans-Pacific Partnership (TPP) negotiations this year, there is a heightened sense of urgency to come to an agreement. This point was reinforced by the start of the 19th round of negotiations in Brunei – just one month after the previous round concluded in Malaysia.

National Psoriasis Foundation Invites You to be a Citizen Pscientist

08.21.13 | By

Many patients are welcoming efforts by biopharmaceutical companies, patient organizations and scientists in academia to actively engage patients in clinical trials and other research opportunities.  It can be empowering to learn more about yourself and your disease, and to know that your participation may even help future patients.

Mental Health and the Biopharmaceutical Pipeline

08.20.13 | By

The New York Times today  put a spotlight on mental health, mistakenly pointing out that we are facing a crisis in innovation for medicines that can help patients suffering from debilitating psychiatric diseases.

Conversations: Clinical Trial Data, Transparency and Patient Privacy

08.20.13 | By

Bringing a medicine to patients, from discovery through FDA review, is a lengthy, costly and sometimes unpredictable process. On average, it takes 10-15 years and an investment of more than $1 billion. As noted previously on the Catalyst, only one out of 5,000-10,000 potential new medicines make it through the multiple and rigorous pre-clinical and clinical trials phases and is ultimately approved by the FDA for patient use.

Pages

Subscribe to RSS - Opinion